Generic Medicine Info
Indications and Dosage
Anorexia and cachexia in patients with cancer or AIDS
Adult: Initial: 800 mg daily. Usual range: 400-800 mg daily. As suspension containing 625 mg megestrol acetate in 5 ml: 625 mg daily.

Palliative treatment of breast carcinoma
Adult: 40 mg 4 times daily or 160 mg once daily.

Palliative treatment of endometrial carcinoma
Adult: 40-320 mg daily in divided doses.
Standard Formulation: Should be taken with food.
Megace Es: May be taken with or without food.
Pregnancy and lactation. Severe hepatic impairment.
Special Precautions
History of thrombophlebitis, mild to moderate hepatic impairment, risk of fluid retention, history of depression, diabetes, hypertension, renal or cardiac dysfunction.
Adverse Reactions
Acne, urticaria, fluid retention, wt gain, heart failure, nausea, vomiting, GI disturbances, changes in libido, breast discomfort, premenstrual symptoms, irregular menstrual cycles, depression, insomnia, somnolence, alopecia, hirsutism, anaphylactoid-like reaction, jaundice, hot flushes, adrenocortical suppression, carpal tunnel syndrome, hypercalcaemia, tumour flare, hypertension.
PO: X (for oral suspension), D (for  tablet)
Drug Interactions
Concentrations of indinavir may be reduced. Possible reduced efficacy of cisplatin. Warfarin half life may be increased. Megestrol concentration may be decreased by aminoglutethimide and enzyme-inducing drugs.
Description: Megestrol is a progestogen used as an antineoplastic and appetite stimulant. The mechanism of it's antineoplastic effects is not known but may be due to inhibition of oestrogen synthesis, modulation of other steroid hormones and/or a direct cytotoxic effect on tumour cells.
Absorption: Variable absorption from the GIT (oral); peak plasma concentrations after 1-3 hrs.
Distribution: Protein-binding: High.
Metabolism: Hepatic.
Excretion: Urine (as steroid metabolites and inactive compound), faeces.
Disclaimer: This information is independently developed by MIMS based on Megestrol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
  • Megaplex
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in